Multiple anti-TNF antibodies and TNF soluble receptors have been approved for use in humans to block TNF-α activity, and are primarily used to treat autoinflammatory conditions, such as rheumatoid arthritis. This evidence concerns the gene TNF and rheumatoid arthritis.